Drugs / ABMSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06997939 | Jun 2025 → May 2027 expected | ischemic stroke | Affiliated Hospital of Nantong University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06997939 ↗ |
| Modality | Cell therapy | “Autologous bone marrow-derived mesenchymal stem cells administered via Ommaya reservoir” NCT06997939 ↗ |
| Route | Other | “administered via Ommaya reservoir” NCT06997939 ↗ |